|
|
Abstract
Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV
Bennett M.1, Johns K.1, Bondy G.2
Objectives: To determine the efficacy and safety of adding ezetimibe to maximally tolerated lipid lowering therapy in patients with HIV.
Methods: We analysed the change in serum concentrations of total cholesterol, LDL, HDL, triglycerides and apolipoprotein B100 in 33 patients with HIV who had been prescribed ezetimibe 10mg per day. All patients were seen in the IDC/HIC Metabolic Clinic, a tertiary referral clinic, and had been prescribed ezetimibe as they had not been at target despite taking maximally tolerated doses of other lipid lowering therapies. In addition, adverse events as defined by an elevation in AST or ALT over 5 times ULN or CK over 10 times ULN or any symptom requiring discontinuation were documented.
Results: Mean total cholesterol was reduced from 6.95 mmol/L to 5.51mmol/L (21% reduction, p<0.001). Mean LDL was reduced from 4.05mmol/L to 2.63mmol/L (35% reduction, p<0.001). Mean HDL increased from 1.07 mmol/L to 1.16 mmol/L (8% increase, p=0.038). Mean triglyceride was reduced from 6.22 mmol/L to 3.85 mmol/L (34% reduction, p=0.006). Mean Apolipoprotein B100 was reduced from 1.45 g/L to 1.09 g/L (33% reduction p=0.043). No adverse events occurred. In our center, in the absence of consensus guidelines for the treatment of dyslipidemia in patients with HIV, we currently use moderate risk lipid profile targets. Following the addition of ezetimibe the total cholesterol was reduced to less than or equal to 5.0mmol/L 13/33 patients (39%) (baseline 0/33). The LDL concentration was reduced to less than or equal to 3.5mmol/L in 15/25 patients (60%) (baseline 6/25). The ratio of total cholesterol to HDL ratio was reduced to less than or equal to 5.0 in 15/33 patients (45%) (baseline 4/33).
Conclusions: Ezetimibe appears safe and effective when added to maximally tolerated lipid lowering therapy in patients with HIV.
4th IAS Conference on HIV Pathogenesis, Treatment and Prevention
Abstract no.
TUPEB075
Suggested Citation
"BennettM., et al.
Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV.
Poster exhibition:
4th IAS Conference on HIV Pathogenesis, Treatment and Prevention:
Abstract no.
TUPEB075"
|
|
|